From:  Survival prediction in triple-negative breast cancer: a Cox model with fairness assessment using ISO/IEC TR 24027:2021 in a MENA cohort

 The variables with their distributions, effect sizes, and P-values.

VariablesOverall (N = 138)No (N = 104)Yes (N = 34)P-valueEffect size
Age
Mean (SD)54.0 (12.5)54.2 (11.9)53.4 (14.4)0.760.06
Median [Min, Max]53.0 [33.0, 85.0]53.0 [33.0, 81.0]51.5 [33.0, 85.0]
Ki-67
< 15%7 (5.1%)4 (3.9%)3 (8.8%)0.300.13
> 35%87 (63.0%)69 (66.3%)18 (52.9%)
15–35%44 (31.9%)31 (29.8%)13 (38.2%)
History of comorbid conditions
No85 (61.6%)61 (58.6%)24 (70.6%)0.270.11
Yes53 (38.4%)43 (41.4%)10 (29.4%)
Lymph
No92 (66.6%)70 (67.3%)22 (64.7%)0.990.02
Yes46 (33.4%)34 (32.7%)12 (35.3%)
Tumor size
< 2 cm37 (26.8%)29 (27.9%)8 (23.5%)< 0.010.27
> 5 cm16 (11.6%)7 (6.7%)9 (26.5%)
2–5 cm85 (61.6%)68 (65.4%)17 (50.0%)
Type of surgery
Lumpectomy91 (65.9%)77 (74.0%)15 (44.1%)< 0.010.28
Radical mastectomy47 (34.1%)27 (26.0%)19 (55.9%)
BC family
No61 (44.2%)45 (43.3%)16 (47.1%)0.890.03
Yes77 (55.8%)59 (56.7%)18 (52.9%)
Recurrence
No130 (94.2%)101 (97.1%)29 (85.3%)0.030.22
Yes8 (5.8%)3 (2.9%)5 (14.7%)
Metastasis
No105 (76.1%)97 (93.3%)8 (23.5%)< 0.010.70
Yes33 (23.9%)7 (6.7%)26 (76.5%)
Grade
G19 (6.5%)7 (6.7%)2 (5.9%)0.900.04
G228 (20.2%)20 (19.2%)8 (23.5%)
G3101 (73.3%)77 (74.0%)24 (70.6%)
Treatment
Chemotherapy19 (13.8%)8 (7.7%)11 (32.4%)< 0.010.31
Chemotherapy + radiotherapy119 (86.2%)96 (92.3%)23 (67.6%)